Ascend Advanced Therapies, an end-to-end gene therapy development partner, has added industry veteran Scott Law as Chief Operations Officer (COO).
 
Law joins an experienced leadership team that includes expertise in gene therapy from the development and services side with the goal of streamlining operational excellence as Ascend evolves.
 
Law brings more than 30 years of global pharmaceutical experience, including senior manufacturing roles at companies such as Telix Pharmaceuticals, Baxter, Emergent BioSolutions, Ferndale Laboratories, and Pfizer. Most recently, he was Senior Vice President of Global Manufacturing and Operations at Telix Pharmaceuticals where he was responsible for the development, manufacture, and commercialization of radiopharmaceutical products.
 
“This is another step in the development of our organization to bring an offering to the market that supports clients from early development all the way through to commercial production. We have state-of-the-art facilities and highly experienced teams that have an established track record of gene therapy development and manufacturing,” Mike Stella, CEO at Ascend said. “Via our recent acquisition, we now have a Coast to Coast offer in the US, and roots in two leading EU markets. Our brand is in an evolution, including updating our name to Ascend Advanced Therapies to reflect our commitment to being the leader in AAV development and manufacturing. The addition of Scott further elevates our depth of talent in this market, which is a key differentiator and mainstay of the foundation at Ascend.”
 
“I am thrilled to be here, working with a team that is building forward from experience developing therapies and understands what it takes to successfully bring them to market. We know that technology is only one piece of the puzzle. We also must have the right level of expertise and execution to continue growing our position as the leading AAV CDMO,” new COO, Scott Law offered.